Physician profile
Robert M Castro
NPI 1285777813
$6,029.67
in general payments reported to CMS, 2019-2025
30 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $638 · 2021: $722 · 2022: $918 · 2023: $563 · 2024: $1,487 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,059 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.90 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,351.83 | 2019-2025 | Accolade Sr, General - Tachy, Resonate El Icd Vr |
| Abbott Laboratories | $535.27 | 2020-2025 | Xience Skypoint, Pressurewire, Coroflow |
| Novartis Pharmaceuticals Corporation | $466.23 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $334.54 | 2019-2025 | Lifevest |
| Pfizer INC. | $314.55 | 2024-2025 | |
| Edwards Lifesciences Corporation | $291.70 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic Vascular, INC. | $274.06 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $238.18 | 2020-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $206.30 | 2021-2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $185.85 | 2019-2021 | |
| Abiomed | $171.37 | 2022-2024 | Impella |
| Medtronic, INC. | $166.74 | 2021-2025 | Onyx Frontier, Symplicity G3 |
| Shockwave Medical, INC | $162.42 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Inari Medical, INC. | $154.12 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Kiniksa Pharmaceuticals, LTD. | $150.68 | 2021-2023 | Arcalyst |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $142.67 | 2024-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $140.73 | 2022-2024 | Xarelto |
| Chiesi USA, INC. | $107.17 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $100.34 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $98.64 | 2021-2025 | Camzyos, Eliquis |
| Cordis US Corp. | $90.77 | 2024 | Mynx Control, Infiniti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.84 | 2021-2022 | |
| Astellas Pharma US INC | $79.78 | 2022-2023 | Cresemba |
| Cardiovascular Systems INC. | $48.83 | 2021-2023 | Diamondback Coronary |
| Novo Nordisk INC | $33.19 | 2025 | Ozempic, Rybelsus |
| Philips North America LLC | $24.14 | 2024 | (Br3) Coronary Other |
| Bridgebio Pharma, INC. | $21.11 | 2025 | Attruby |
| Stryker Corporation | $19.88 | 2025 | Flowtriever |
| Bayer Healthcare Pharmaceuticals INC. | $17.67 | 2025 | |
| Preventice Services, LLC | $14.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.